Horizon’s teprotumumab hits major R&D milestone
Horizon Pharma has announced positive Phase III clinical trial data for teprotumumab, as a treatment for active thyroid eye disease (TED).
Read More
Tag: Teprotumumab
Horizon completes enrollment in TED trial early
Horizon Pharma says it has completed enrollment in a confirmatory Phase III trial of teprotumumab in patients living with moderate-to-severe active thyroid eye disease (TED) ahead of schedule.
Read More
Horizon Pharma enrolls first patient in TED trial
Horizon Pharma has enrolled the first patient in a Phase III clinical trial assessing its experimental medicine teprotumumab for moderate-to-severe active thyroid eye disease (TED).
Read More
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
